Life Science Partner recruits former Vice President, Finance and CFO of Serologicals Corporation who led company through $1.3 B acquisition
Life Science Partner announces the recruitment of Harold W. (Bud) Ingalls to CardioMEMS, Inc. as the Chief Financial Officer. CardioMEMS is an early stage medical device company focused on the application of Microelectromechanical systems (MEMS) technology to create innovative devices for the diagnosis and management of chronic diseases. CardioMEMS is developing and commercializing implantable wireless sensors targeted for the Abdominal Aortic Aneurysm (AAA) and Congestive Heart Failure (CHF) markets.
In Ingalls’ previous role as CFO of Serologicals, a public life sciences company, he was instrumental in executing on a strategic high-growth, mergers-oriented business plan and negotiating its $1.3 B acquisition by Millipore. Earlier, his general management skills were evident as he was President and CEO of Roche Industries, a $500 M international commodity and specialty chemicals manufacturer.
“Bud has a diverse operating and financial background with more than 20 years in the senior leadership role in technology-based companies,” noted Tom Callaway, MD, founder and president of Life Science Partner. “He knows how to finance a company for accelerated growth, and is a proven public company CFO.”
Ingalls will join the executive management team with the primary responsibility for the continued private and public financing of the Company’s operations, including the expansion of the technology platform and the launch of additional products. In addition, he will oversee a small team with responsibility for the analysis and review of the company’s financial data, performance, expenditures and costs.
Ingalls received his Bachelor of Business Administration degree from the University of Wisconsin in Madison, Wisconsin.